Akari Therapeutics gets Nasdaq bid-price deficiency notice

Akari Therapeutics has received a notice from Nasdaq that its American Depositary Shares (ADSs) no longer meet the exchange’s minimum bid price requirement of $1.00 per share.

Rhea-AI Filing Summary

Akari Therapeutics has received a notice from Nasdaq that its American Depositary Shares (ADSs) no longer meet the exchange’s minimum bid price requirement of $1.00 per share. The ADSs closed below this level for 30 consecutive business days, triggering a deficiency under Nasdaq Listing Rule 5550(a)(2). The notice does not immediately affect trading, and the ADSs will continue to trade on the Nasdaq Capital Market under the symbol AKTX.

Akari has 180 calendar days, until May 25, 2026, to regain compliance by having its ADSs close at or above $1.00 for at least 10 consecutive business days. If it still does not meet the requirement, it may qualify for an additional 180-day period if it satisfies other Nasdaq listing standards, or it could ultimately face delisting, with the right to appeal. The company plans to monitor its share price and may consider options such as changing the ADS ratio to restore compliance.

Positive

• None.

Negative

• Nasdaq bid-price noncompliance and delisting risk: Akari’s ADSs failed to meet Nasdaq’s $1.00 minimum bid for 30 consecutive business days, starting a compliance clock that could lead to delisting if unresolved.

Insights

Equity market structure analyst

Nasdaq bid-price deficiency raises delisting risk if Akari cannot lift its ADS price.

Akari Therapeutics has fallen out of compliance with Nasdaq’s minimum bid price rule after its ADSs traded below $1.00 for 30 consecutive business days. This places the stock in a formal deficiency status, although trading on the Nasdaq Capital Market continues under the symbol AKTX.

The company has 180 calendar days, until May 25, 2026, to get its closing bid price back to at least $1.00 for 10 consecutive business days. If it meets other initial listing standards, it may receive a second 180-day period; otherwise, Nasdaq can move toward delisting, subject to an appeal process.

Akari states it will monitor its ADS price and may consider options such as a change in the ADS ratio, which can mechanically increase the per-ADS price. Actual outcomes will depend on future market trading and any corporate actions the company chooses to take within the Nasdaq timeframes.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

FAQ

What did Akari Therapeutics (AKTX) announce in this 8-K filing?

Akari Therapeutics reported that Nasdaq notified the company its American Depositary Shares no longer meet the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market.

Why is Akari Therapeutics out of compliance with Nasdaq listing rules?

Nasdaq Listing Rule 5550(a)(2) requires a minimum bid price of $1.00 per share. Akari’s ADSs closed below this level for 30 consecutive business days, triggering a bid-price deficiency.

How long does Akari Therapeutics have to regain Nasdaq bid-price compliance?

Akari has 180 calendar days, until May 25, 2026, to regain compliance by achieving a closing bid price of at least $1.00 per ADS for a minimum of 10 consecutive business days.

What happens if Akari does not regain compliance by May 25, 2026?

If Akari does not regain compliance by May 25, 2026, it may qualify for an additional 180-day period if it meets other Nasdaq listing standards. If it does not qualify or still fails to comply, Nasdaq may determine to delist the ADSs, and Akari could then appeal to a Hearings Panel.

Is Akari Therapeutics still trading on Nasdaq after the deficiency notice?

Yes. The notice has no immediate effect on the listing or trading of Akari’s ADSs. They continue to trade on the Nasdaq Capital Market under the ticker symbol AKTX.

What steps might Akari take to regain Nasdaq bid-price compliance?

Akari states it intends to monitor the closing bid price of its ADSs and may consider available options, including potentially implementing a ratio change of its ADSs, to regain compliance with Nasdaq’s minimum bid price rule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/26/2025 - 05:00 PM Learn about SEC filing dates

false 0001541157 0001541157 2025-11-24 2025-11-24 0001541157 AKTX:AmericanDepositarySharesEachRepresenting2000OrdinarySharesMember 2025-11-24 2025-11-24 0001541157 AKTX:OrdinarySharesParValue0.0001PerShareMember 2025-11-24 2025-11-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 24, 2025

Akari Therapeutics, Plc

(Exact name of Registrant as Specified in Its Charter)

England and Wales		001-36288		98-1034922
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

401 East Jackson Street, Suite 3300 Tampa, FL		33602
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (929) 274-7510

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
American Depositary Shares, each representing 2000 Ordinary Shares		AKTX		The Nasdaq Stock Market LLC
Ordinary Shares, par value $0.0001 per share*		N/A		The Nasdaq Stock Market LLC

*Trading, but only in connection with the American Depositary Shares.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On November 24, 2025, Akari Therapeutics, Plc (the “Company”) was notified (the “Notification Letter”) by the Nasdaq Listing Qualifications (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s American Depositary Shares (the “ADSs”), each representing 2,000 ordinary shares of the Company, par value $0.0001 per share, for the 30 consecutive business days prior to the date of the Notification Letter, the Company no longer meets the minimum bid price requirement. The Notification Letter has no immediate effect on the listing or trading of the ADSs on the Nasdaq Capital Market and, at this time, the ADSs will continue to trade on the Nasdaq Capital Market under the symbol “AKTX”.

The Notification Letter provides that the Company has 180 calendar days, or until May 25, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the ADSs must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by May 25, 2026, the Company may then be eligible for additional 180 days if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period. If the Company does not qualify for the second compliance period or fails to regain compliance during the second compliance period, then Nasdaq will notify the Company of its determination to delist the Company’s ADSs, at which point the Company will have an opportunity to appeal the delisting determination to a Hearings Panel.

The Company intends to monitor the closing bid price of its ADSs and may, if appropriate, consider implementing available options, including, but not limited to, implementing a ratio change of its ADSs, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Akari Therapeutics, Plc
Date:	November 26, 2025	By:	/s/ Abizer Gaslightwala
		Name:	Abizer Gaslightwala
		Title:	President and Chief Executive Officer